Quinoline derivatives and their use as 5-ht6 ligands
AssigneeGlaxo Group Limited
InventorsMahmood AHMED, Christopher Norbert Johnson, Martin C. Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty
Life of this patent
Estimating the term…
Abstract
Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
Claims18
A method of treating a patient suffering from a disorder selected from anxiety, depression, epilepsy, an obsessive compulsive disorder, migraine, Parkinsons Disease, ADHD, a sleep disorder, a feeding disorder, a panic attack, withdrawal from drug abuse, schizophrenia, stroke, a disorder associated with spinal trauma and/or head injury and irritable bowel syndrome, which method comprises administering a therapeutically effective amount of a compound of formula (I):
- wherein:
- R1 represents hydrogen, methyl, ethyl, isopropyl, isobutyl or 2,2-dimethylpropyl;
- R2 represents hydrogen or methyl or is linked to R1 to form a group (CH2)3;
- R3 represents hydrogen, methyl or halogen;
- R4 and R5 independently represent hydrogen, or methyl;
- m represents 1 or 2, or m is 2 and both R2 groups are linked to form a CH2 group linking C-2 and C-5 of the piperizine ring;
- n represents 1;
- p represents 1 or 2;
- A represents a group —Ar1 wherein Ar1 represents unsubstituted phenyl or phenyl substituted by halogen, cyano, C1-6alkyl, C1-6alkoxy, trifluoromethyl or trifluoromethoxy,
- or a pharmaceutically acceptable salt thereof,
- to a patient in need thereof.
A method of treating a patient suffering from a cognitive memory disorder associated with Parkinsons disease, which method comprises administering a therapeutically effective amount of a compound of formula (I):
- wherein:
- R1 represents hydrogen, methyl, ethyl, isopropyl, isobutyl or 2,2-dimethylpropyl;
- R2 represents hydrogen or methyl or is linked to R1 to form a group (CH2)3;
- R3 represents hydrogen, methyl or halogen;
- R4 and R5 independently represent hydrogen, or methyl;
- m represents 1 or 2, or m is 2 and both R2 groups are linked to form a CH2 group linking C-2 and C-5 of the piperizine ring;
- n represents 1;
- p represents 1 or 2;
- A represents a group —Ar1 wherein Ar1 represents unsubstituted phenyl or phenyl substituted by halogen, cyano, C1-6alkyl, C1-6alkoxy, trifluoromethyl or trifluoromethoxy,
- or a pharmaceutically acceptable salt thereof,
- to a patient in need thereof.
Dependencies are inferred from the claim text.